Novo Nordisk’s (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.
Eli Lilly Vs. Novo Nordisk: Correction Overly Done – GLP-1 Market Leadership/ Robust Pipelines Ahead
view original post